A clear vial labeled "Optic Labs 5-Amino-1MQ 10mg" (Purity ≥99%) sits against a light purple background, sealed with a silver cap. This Australian peptide is known for supporting metabolic regulation. Optic Labs Au

5-Amino-1MQ 10mg

$71.99
Sale price  $71.99 Regular price  $89.99
Skip to product information
A clear vial labeled "Optic Labs 5-Amino-1MQ 10mg" (Purity ≥99%) sits against a light purple background, sealed with a silver cap. This Australian peptide is known for supporting metabolic regulation. Optic Labs Au

5-Amino-1MQ 10mg

$71.99
Sale price  $71.99 Regular price  $89.99

Buy high-purity 5-Amino-1MQ in Australia (10mg). Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About 5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule research compound and a selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT consumes S-adenosylmethionine (SAM) and methylates nicotinamide, depleting cellular methyl pools and downstream NAD+ precursors; pharmacological inhibition of NNMT has therefore become a major focus in laboratory research on adipose-tissue energy balance, methyl-donor recycling, and metabolic resilience.

Optic Labs supplies 5-Amino-1MQ as a lyophilised research-grade powder for laboratories investigating NNMT-mediated metabolic pathways, adipocyte biology, and ageing-related cellular remodelling. Each vial is third-party HPLC verified at >99% purity. 5-Amino-1MQ is supplied for laboratory research use only and is not intended for human consumption, cosmetic application, or any therapeutic purpose.

Product specifications

  • Compound: 5-Amino-1-methylquinolinium iodide (5-Amino-1MQ)
  • CAS number: 75413-77-3
  • Molecular formula: C10H11IN2
  • Molecular weight: ~286.1 g/mol
  • Class: Small-molecule NNMT inhibitor (not a peptide)
  • Form: Lyophilised powder
  • Purity: >99% by HPLC
  • Available sizes: 10mg vial
  • Storage: 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.
  • Origin: Manufactured to research-grade specifications, third-party HPLC verified
  • Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

5-Amino-1MQ emerged from medicinal-chemistry programmes screening for selective NNMT inhibitors. NNMT had previously been identified as upregulated in obese adipose tissue, several solid tumours, and ageing tissue more broadly, where its activity correlates with depleted SAM and elevated 1-methylnicotinamide (MNA). 5-Amino-1MQ binds the NNMT active site with high selectivity and is widely used in published research as a chemical probe for NNMT function.

  • NNMT enzyme inhibition — biochemical studies have characterised 5-Amino-1MQ as a potent, selective NNMT inhibitor in cell-free and cell-culture assays.
  • Adipocyte energy expenditure — published animal models have explored NNMT inhibition with 5-Amino-1MQ in diet-induced-obesity rodents, examining adipose-tissue mass, energy expenditure, and metabolic markers.
  • SAM and methyl-donor pools — laboratory work has tracked changes in cellular SAM, SAH and 1-methylnicotinamide levels following NNMT inhibition.
  • NAD+ salvage interactions — research has examined the relationship between NNMT activity, nicotinamide availability and downstream NAD+ salvage flux.
  • Skeletal muscle ageing models — preclinical investigation has explored NNMT inhibition in models of age-related muscle dysfunction and stem-cell quiescence.
  • Cancer-cell metabolism studies — NNMT is overexpressed in several cancer cell lines, and 5-Amino-1MQ has been used in vitro to characterise its role in tumour metabolism.
  • Hepatic lipid handling — animal-model studies have examined hepatic steatosis and lipid metabolism following NNMT inhibition.

For broader context on metabolic and longevity peptide research, see our NAD+ longevity research guide and our what are peptides explainer. Researchers working with reconstitution should also reference our peptide reconstitution guide.

Reconstitution and handling

5-Amino-1MQ is supplied as a lyophilised powder and is reconstituted prior to use with sterile bacteriostatic water. A common laboratory approach is to add 2 mL of bac water to a 10mg vial, yielding a 5 mg/mL working concentration; at this concentration, 0.1 mL drawn into an insulin syringe corresponds to 500 µg of compound. As 5-Amino-1MQ is a small molecule rather than a long-chain peptide, it is generally well behaved in solution. Reconstituted material should be stored at 2–8°C, protected from light, and used within 30 days. For step-by-step dilution mathematics, see our reconstitution calculator guide and our peptide storage research guide.

Commonly stacked research peptides

In published metabolic and longevity research, 5-Amino-1MQ is often referenced alongside other compounds investigated for energy-expenditure, NAD+ and methyl-pool research:

  • NAD+ — directly relevant to the methyl/nicotinamide axis modulated by NNMT inhibition.
  • Retatrutide — GLP-1/GIP/glucagon triple agonist studied in adiposity and metabolic-rate research.
  • AOD-9604 — hGH (177–191) fragment investigated for adipose lipolysis research.
  • MOTS-c — mitochondrial-derived peptide investigated in metabolic and ageing models.
  • Glutathione — tripeptide antioxidant cross-referenced with 5-Amino-1MQ in redox and methyl-pool research.

For broader context on multi-compound research designs, see our peptide research stacks overview.

Frequently asked questions

Is 5-Amino-1MQ legal in Australia?

5-Amino-1MQ is supplied by Optic Labs strictly for laboratory research, development and analytical use. It is not approved by the Therapeutic Goods Administration for human therapeutic use and is not a registered medicine. For a detailed overview of Australian research-compound regulation, see our guide to peptide legality and TGA compliance in Australia.

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule research compound that selectively inhibits nicotinamide N-methyltransferase (NNMT). It is not a peptide; it is a methylated quinolinium derivative used as a chemical probe in metabolic and ageing research. See our what are peptides explainer for broader context on the wider research-compound landscape.

What does 5-Amino-1MQ research focus on?

Published research has examined 5-Amino-1MQ in cell-culture and animal models of obesity, adipose-tissue energy expenditure, NAD+/SAM methyl-pool dynamics, hepatic lipid metabolism and ageing-related cellular function. It is studied as an NNMT inhibitor rather than a metabolic or weight-loss treatment.

How is 5-Amino-1MQ supplied?

Optic Labs supplies 5-Amino-1MQ as a lyophilised powder in glass research vials, available in 10mg. Each vial is sealed and shipped with a tamper-evident seal. Certificates of analysis showing HPLC purity testing are available on request.

How much bacteriostatic water do I mix with a 5-Amino-1MQ 10mg vial?

A common laboratory dilution is 2 mL of bacteriostatic water per 10mg vial, giving a 5 mg/mL solution. The exact volume depends on your research protocol — see our reconstitution calculator guide for dilution mathematics.

How should reconstituted 5-Amino-1MQ be stored?

Reconstituted 5-Amino-1MQ should be kept at 2–8°C, protected from light, and used within 30 days. Long-term storage of unreconstituted lyophilised powder should be at −20°C or colder. See our peptide storage complete research guide for handling detail.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.

You may also like